On November 5, 2015 Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, http://www.pvct.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus"), reported its results of operations and financial condition for the third quarter ended September 30, 2015 (Filing, 8-K, Provectus Pharmaceuticals, NOV 5, 2015, View Source [SID:1234507975]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Provectus will also hold its quarterly business update conference call at 5 p.m. (EST) today to provide a business update on PV-10 and PH-10 to the investment community and answer questions from investors.

Those who wish to participate in the conference call may telephone 877-407-4019 from the U.S. International callers may telephone 201-689-8337 approximately fifteen minutes before the call. A webcast will also be available at www.pvct.com.
A digital replay will be available by telephone approximately two hours after the completion of the call until January 31, 2016 and may be accessed by dialing 877-660-6853 from the U.S. or 201-612-7415 for international callers, and using the Conference ID #13623105.

Third Quarter Financial Results and Balance Sheet Highlights
The Company’s cash and cash equivalents were $18.9 million as of September 30, 2015. This is an increase of $1.5 million from the $17.4 million reported as of December 31, 2014.

Stockholders’ equity at September 30, 2015, was $24,529,437. This compares to stockholders’ equity at December 31, 2014, of $25,189,876.

For additional information regarding Provectus’ results of operations and financial condition for the third quarter ended September 30, 2015, please see Provectus’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 5, 2015.